Methotrexate showed no clear difference in remission and complete withdrawal from steroids compared with placebo (low certainty).
It is very uncertain whether enteral nutrition changes remission rate ‐ ITT compared with corticosteroids (very low certainty).
It is very uncertain whether enteral nutrition changes remission rate ‐ ITT adult studies compared with corticosteroids (very low certainty).
It is very uncertain whether enteral nutrition changes remission rate ‐ ITT pediatric studies compared with corticosteroids (very low certainty).
It is very uncertain whether enteral nutrition changes remission rate ‐ per‐protocol ‐ pediatric studies compared with corticosteroids (very low certainty).
It is very uncertain whether enteral nutrition changes adverse events compared with corticosteroids (very low certainty).
It is very uncertain whether enteral nutrition changes withdrawal due to adverse events compared with corticosteroids (very low certainty).
Delayed‐release mesalamine (3 ‐ 4.5 g/day) showed no clear difference in induction of remission (CDAI < or =150 with or without decrease of… compared with corticosteroids (moderate certainty).
Sulfasalazine probably leads to lower induction of remission (CDAI <150) compared with corticosteroids (moderate certainty).
Sulfasalazine probably leads to lower induction of remission compared with sulfasalazine and corticosteroids (moderate certainty).
Budesonide 9 mg probably leads to lower induction of clinical remission (CDAI < 150) ‐ 8 weeks compared with conventional steroids (moderate certainty).
Budesonide 9 mg showed no clear difference in withdrawal due to adverse events compared with conventional steroids (low certainty).
It is very uncertain whether budesonide 9 mg changes withdrawal due to disease worsening compared with conventional steroids (very low certainty).
It is very uncertain whether UFH changes clinical improvement compared with corticosteroids (very low certainty).